PulmonologyNews.net

Pulmonology Xagena

Omalizumab ( Xolair ) has been recommended as an add-on option for the treatment of patients with moderate-severe allergic asthma uncontrolled with high doses of corticoid inhaled therapy. In addition ...


Once-daily Tiotropium ( Spiriva ) Respimat, a long-acting anticholinergic bronchodilator, has been shown in a phase III program to improve lung function and reduce severe exacerbation risk in severe a ...


Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease ( COPD ). A study has c ...


Present guidelines for the diagnosis of idiopathic pulmonary fibrosis require histological confirmation of surgical lung biopsy samples when high-resolution CT images are not definitive for usual inte ...


Acetylcysteine has been suggested as a beneficial treatment for idiopathic pulmonary fibrosis, although data from placebo-controlled studies are lacking. In the initial double-blind, placebo-contro ...


Despite currently available therapies and detailed guidelines, many people with mild asthma remain symptomatic; it is important to establish the efficacy and safety of new treatments in this group. ...


Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without or ...


Nintedanib is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of Nintedanib twice daily reduced lung-function decline and acute ...


Eczema, rhinitis, and asthma often coexist ( comorbidity ) in children, but the proportion of comorbidity not attributable to either chance or the role of IgE sensitisation is unknown. Researchers hav ...


Novel treatment options are urgently needed for multidrug-resistant ( MDR ) and extensively drug-resistant ( XDR ) tuberculosis, which are associated with immune dysfunction and poor treatment outcome ...


The double blind, randomised and placebo-controlled IMPULSIS trials, involving 1,066 patients across 24 countries, evaluated the effect of oral Nintedanib 150 mg twice daily, on the annual rate of dec ...


The ACLIFORM/COPD study has assessed the efficacy and safety of two doses of twice-daily ( BID ) Aclidinium bromide / Formoterol fumarate fixed-dose combination ( FDC ) in patients with moderate-to-se ...


QVA149 ( Ultibro Breezhaler ), a novel, once-daily dual bronchodilator containing the long-acting beta2-agonist, Indacaterol and long-acting muscarinic antagonist Glycopyrronium, improves lung functio ...


COPD exacerbations are linked to a rapid decline in lung function and increased mortality. QVA149 ( Ultibro Breezhaler ) is a once-daily dual bronchodilator with a fixed-dose combination of long-actin ...


Results from two phase III studies were presented. They have shown that patients with chronic obstructive pulmonary disease ( COPD ) who received the anticholinergic, Incruse Ellipta ( Umeclidinium 62 ...